[1] Krentz AJ,Bailey CJ.Oral antidiabetic agents:current role in type 2 diabetes mellitus[J].Drugs,2005,65(3):385.
[2] Johansen K.Efficacy of metformin in the treatment of NIDDM,mea-analysis[J].Diabetes care,1999;22(1):33.
[3] Wildasin EM,Skaar DJ,Kirchain WR,et al.Metformin, apromising oral antihyperglycemic for the treatment of noninsulin-dependent diabetes mellitus[J].J Pharmacother,1997,17(1):62.
[4] Graham GG,Punt J,Arora M,et al.Clinical pharmacokinetics of metformin[J].Clin Pharmacokinet,2011,50(2):81.
[5] Jabbour S,Ziring B.Advantages of extended-release metformin in patients with type 2 diabetes mellitus[J].Postgrad Med,2011,123(1):15.
[6] Schwartz SL,Gordi T,Hou E,et al.Clinical development of metformin extendedrelease tablets for type 2 diabetes:an overview. Expert Opin Drug Metab Toxicol[J].2008,4(9):1235.
[7] Cullen E, Liao J,Lukacsko P,et al.Pharmacokinetics and dose proportionality of extended-release metformin following administration of 1 000,1 500,2 000 and 2 500 mg in healthy volunteers[J].Biopharm Drug Dispos,2004,25(6):261.
[8] Sheiner LB,Rosenberg B,Marathe VV.Estimation of population characteristics of pharmacokinetic parameters from routine clinical data[J].J Pharmacokinet Biopharm,1977,5(5):445.[JP+1]
[9] Vozeh S,Steimer JL,Rowland M,et al.The use of population pharmacokinetics in drug development[J].Clin Pharmacokinet,1996,30(2):81.[JP+1]
[10] Aarons L,Balant LP,Mentré F,et al.Population approaches in drug development.Report on an expert meeting to discuss population pharmacokinetic/pharmacodynamic software[J].Eur J Clin Pharmacol,1994;46(5):389.
[11] Hong Y,Rohatagi S,Habtemariam B,et al.Population exposureresponse modeling of metformin in patients with type 2 diabetes mellitus[J].J Clin Pharmacol,2008,48(6):696.[JP3]
[12] Charles B,Norris R,Xiao X,et al.Population pharmacokinetics of metformin in late pregnancy[J].Ther Drug Monit,2006,28(1):67.
[13] 厉伟兰,刘晓东,谢 林,等.二甲双胍缓释片人体药代动力学及其相对生物利用度[J].江苏药学与临床研究,2006,14(2):72.
[14] 汤 净,钟国平,刘伟东,等.国产盐酸二甲双胍缓释片的人体药动学及相对生物利用度[J].中国新药杂志,2005,14(2):197.
[15] 廉江平,张 鹏,李小川,等.盐酸二甲双胍缓释片的药代动力学及相对生物利用度研究[J].西北药学杂志,2007,22(5):227.
[16] 陈勇川,何菊英,唐 敏,等.盐酸二甲双胍缓释片人体相对生物利用度及其药代动力学研究[J].第三军医大学学报,2005,27(21):2148.
[17] 杨 洁,张银娣,胡 刚,等.盐酸二甲双胍缓释片人体药代动力学和相对生物利用度研究[J].南京医科大学学报:自然科学版,2007,27(9):920.
[18] 郑 恒,陈雅丽,王 莉,等.盐酸二甲双胍缓释片药物动力学及生物等效性研究[J].华中科技大学学报:医学版,2007,36(4):517.
[19] 温新国,张霖泽,黄 民,等.盐酸二甲双胍缓释片与国外上市品的药动学比较及体内外相关性研究[J].广东药学院学报,2005,21(3):284.
[20] Proctor WR,Bourdet DL,Thakker DR.Mechanisms underlying saturable intestinal absorption of metformin[J].Drug Metab Dispos,2008,36(8):1650.
[21] Robert F,Fendri S,Hary L,et al.Kinetics of plasma and erythrocyte metformin after acute administration in healthy subjects[J].Diabetes Metab,2003,29(3):279.
[22] Briggs GG,Ambrose PJ,Nageotte MP,et al.Excretion of metformin into breast milk and the effect on nursing infants[J].Obstet Gynecol,2005,105(6):1437.
[23] Pillans PI,Landsberg PG,Fleming AM,et al.Evaluation of dosage adjustment in patients with renal impairment[J].Intern Med J,2003,33(1-2): 10.
[24] Stepensky D,Friedman M,Raz I,et al.Pharmacokinetic-pharmacodynamic analysis of the glucose-lowering effect of metformin in diabetic rats reveals first-pass pharmacodynamic effect[J].Drug Metab Dispos,2002,30(8):861.
[25] Lee SH,Kwon KI.Pharmacokinetic-pharmacodynamic modeling for the relationship between glucose-lowering effect and plasma concentration of metformin in volunteers[J].Arch Pharm Res,2004,27(7):806.
[26] Sun L,Kwok E,Gopaluni B,et al.Pharmacokinetic-pharmacodynamic modeling of metformin for the treatment of type II diabetes mellitus[J].Open Biomed Eng J,2011,5,1.